Artivion, Inc. (NYSE:AORT) Receives $47.83 Consensus PT from Analysts

Shares of Artivion, Inc. (NYSE:AORT) have earned a consensus recommendation of “Moderate Buy” from the eight brokerages that are currently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a hold rating and seven have issued a buy rating on the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $47.8333.

A number of research analysts recently issued reports on AORT shares. Needham & Company LLC decreased their price target on shares of Artivion from $58.00 to $44.00 and set a “buy” rating for the company in a research note on Friday, May 8th. LADENBURG THALM/SH SH upgraded shares of Artivion from a “neutral” rating to a “buy” rating and set a $42.00 price target for the company in a research note on Friday, April 10th. Canaccord Genuity Group decreased their price target on shares of Artivion from $51.00 to $48.00 and set a “buy” rating for the company in a research note on Friday, February 13th. Citizens Jmp decreased their price target on shares of Artivion from $53.00 to $48.00 and set a “market outperform” rating for the company in a research note on Friday, May 8th. Finally, Wall Street Zen downgraded shares of Artivion from a “buy” rating to a “hold” rating in a research note on Saturday, April 25th.

Artivion Stock Down 1.4%

Shares of Artivion stock opened at $22.45 on Friday. Artivion has a 52-week low of $19.16 and a 52-week high of $48.25. The company has a 50 day moving average of $33.37 and a 200 day moving average of $39.60. The company has a quick ratio of 2.80, a current ratio of 3.86 and a debt-to-equity ratio of 0.48. The company has a market capitalization of $1.09 billion, a P/E ratio of 93.53 and a beta of 1.41.

Insider Activity at Artivion

In other Artivion news, SVP Jean F. Holloway sold 8,962 shares of the firm’s stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average price of $38.00, for a total transaction of $340,556.00. Following the sale, the senior vice president owned 185,095 shares of the company’s stock, valued at approximately $7,033,610. This trade represents a 4.62% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CAO Amy Horton sold 901 shares of the firm’s stock in a transaction that occurred on Tuesday, March 3rd. The stock was sold at an average price of $37.78, for a total transaction of $34,039.78. Following the sale, the chief accounting officer directly owned 139,088 shares in the company, valued at approximately $5,254,744.64. The trade was a 0.64% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 133,043 shares of company stock valued at $4,977,158 in the last quarter. Company insiders own 6.30% of the company’s stock.

Institutional Trading of Artivion

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. SG Americas Securities LLC raised its holdings in Artivion by 578.4% during the fourth quarter. SG Americas Securities LLC now owns 39,030 shares of the company’s stock worth $1,780,000 after purchasing an additional 33,277 shares in the last quarter. Public Sector Pension Investment Board raised its holdings in Artivion by 23.7% during the third quarter. Public Sector Pension Investment Board now owns 161,970 shares of the company’s stock worth $6,858,000 after purchasing an additional 30,989 shares in the last quarter. JPMorgan Chase & Co. raised its holdings in Artivion by 338.2% during the third quarter. JPMorgan Chase & Co. now owns 122,199 shares of the company’s stock worth $5,174,000 after purchasing an additional 94,312 shares in the last quarter. Kennedy Capital Management LLC raised its holdings in Artivion by 19.0% during the third quarter. Kennedy Capital Management LLC now owns 437,792 shares of the company’s stock worth $18,536,000 after purchasing an additional 70,030 shares in the last quarter. Finally, Vanguard Group Inc. raised its holdings in Artivion by 4.7% during the fourth quarter. Vanguard Group Inc. now owns 3,170,089 shares of the company’s stock worth $144,588,000 after purchasing an additional 141,030 shares in the last quarter. Institutional investors and hedge funds own 86.37% of the company’s stock.

Artivion Company Profile

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.